These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9610919)

  • 1. Conditioned place preference induced by a combination of L-dopa and a COMT inhibitor, entacapone, in rats.
    Katajamäki J; Honkanen A; Piepponen TP; Lindén IB; Zharkovsky A; Ahtee L
    Pharmacol Biochem Behav; 1998 May; 60(1):23-6. PubMed ID: 9610919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
    Napolitano A; Bellini G; Borroni E; Zürcher G; Bonuccelli U
    Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone.
    Nissinen E; Lindén IB; Schultz E; Pohto P
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Sep; 346(3):262-6. PubMed ID: 1407012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.
    Törnwall M; Kaakkola S; Tuomainen P; Kask A; Männistö PT
    Br J Pharmacol; 1994 May; 112(1):13-8. PubMed ID: 7518301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
    Lyras L; Zeng BY; McKenzie G; Pearce RK; Halliwell B; Jenner P
    J Neural Transm (Vienna); 2002; 109(1):53-67. PubMed ID: 11793162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
    Hamaue N; Ogata A; Terado M; Tsuchida S; Yabe I; Sasaki H; Hirafuji M; Togashi H; Aoki T
    Brain Res; 2010 Jan; 1309():110-5. PubMed ID: 19879254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
    Brannan T; Prikhojan A; Yahr MD
    J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat.
    Gerlach M; van den Buuse M; Blaha C; Bremen D; Riederer P
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Nov; 370(5):388-94. PubMed ID: 15502970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yokukansan, a Traditional Japanese Medicine, Enhances the L-DOPA-Induced Rotational Response in 6-Hydroxydopamine-Lesioned Rats: Possible Inhibition of COMT.
    Ishida Y; Ebihara K; Tabuchi M; Imamura S; Sekiguchi K; Mizoguchi K; Kase Y; Koganemaru G; Abe H; Ikarashi Y
    Biol Pharm Bull; 2016; 39(1):104-13. PubMed ID: 26725433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of dopamine-induced natriuresisby the dopamine-metabolizing enzyme catechol-O-methyltransferase.
    Odlind C; Göransson V; Reenilä I; Hansell P
    Exp Nephrol; 1999; 7(4):314-22. PubMed ID: 10450019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase.
    Törnwall M; Tuomainen P; Männistö PT
    Eur J Pharmacol; 1993 Aug; 239(1-3):39-45. PubMed ID: 8223912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
    Huang L; Deng M; Zhang S; Fang Y; Li L
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.
    Brusa L; Pierantozzi M; Bassi A; Fedele E; Lunardi G; Giacomini P; Stanzione P
    Neurol Sci; 2004 Jun; 25(2):53-6. PubMed ID: 15221622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
    Männistö PT; Tuomainen P; Tuominen RK
    Br J Pharmacol; 1992 Mar; 105(3):569-74. PubMed ID: 1628144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.
    Sawle GV; Burn DJ; Morrish PK; Lammertsma AA; Snow BJ; Luthra S; Osman S; Brooks DJ
    Neurology; 1994 Jul; 44(7):1292-7. PubMed ID: 8035933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum.
    Kaakkola S; Wurtman RJ
    J Neurochem; 1993 Jan; 60(1):137-44. PubMed ID: 8417137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Gordin A; Kultalahti ER; Teräväinen H; Sovijärvi A
    Parkinsonism Relat Disord; 2002 Jun; 8(5):349-55. PubMed ID: 15177064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of L-DOPA.
    Asanuma M; Miyazaki I
    BMC Neurosci; 2016 Jul; 17(1):52. PubMed ID: 27456338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
    Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
    Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.